Drug Trial Radar · NCT03427814
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
136
Actual
Start
Jul 3, 2018
Primary completion
Jun 18, 2020
Study completion Jan 3, 2023
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Feb 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 (pamiparib) (versus placebo) will improve progression-free survival (PFS) in participants with advanced or inoperable gastric cancer.
Conditions
- Advanced or Inoperable Gastric Cancer
Interventions
PamiparibDrug
60 mg orally twice daily
PlaceboDrug
60 mg orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) by Investigator AssessmentTime frame: Approximately 23 months
Locations
65 sites in 16 countries. Site status is shown where the registry gives one.
Miami Cancer Institute
Miami, Florida
Scri Florida Cancer Specialist East
West Palm Beach, Florida
Goshen Center For Cancer Care
Goshen, Indiana
Cancer Center of Kansas
Wichita, Kansas
Norton Cancer Institute
Louisville, Kentucky
Novant Health Hematology Charlotte
Charlotte, North Carolina
Oregon Health and Science University
Portland, Oregon
Gosford Hospital
Gosford, New South Wales, Australia
Monash Health
Clayton, Victoria, Australia
Ballarat Oncology and Haematology Services
Wendouree, Victoria, Australia
St John of God Health Care
Subiaco, Western Australia, Australia
Az Sint Jan Brugge
Bruges, Belgium
University Hospitals Leuven
Leuven, Belgium
Anhui Provincial Hospital
Hefei, Anhui, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China
Shandong Cancer Hospital
Jinan, Shandong, China
The Affiliated Hospital of Qingdao University Branch South
Qingdao, Shandong, China
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Fakultni Nemocnice Bulovka
Prague, Czechia
Chru de Brest Hospital Morvan
Brest, France
Chu Besancon Hopital Jean Minjoz
Doubs, France
Hopital Prive Jean Mermoz
Lyon, France
Icm Val Daurelle Oncologie Medicale
Montpellier, France
Hopital Prive Des Cotes Darmor Service Oncologie
Plérin, France
Centre Eugene Marquis
Rennes, France
Ico Site Rene Gauducheau
SaintHerblain, France
Iuc Toulouse Oncopole
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Acad Fridon Todua Medical Center Ltd Research Institute of Clinical Medicine Ltd
Tbilisi, Georgia
Queen Mary Hospital
Hong Kong, Hong Kong
Orszagos Onkologiai Intezet
Budapest, Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont
Pécs, Hungary
Nho Kyushu Cancer Center
Fukuoka, Fukuoka, Japan
Kindai University Nara Hospital
Ikoma, Nara, Japan
Oita University Hospital
Yufushi, Oita Prefecture, Japan
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.